Victor Yang, MD
Gastroenterology · Houston, TXNPI 1023004470
Payments from drug & device makers
Across 545 payments — averaging $84.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$37K
- AbbVie$2K
- Johnson & Johnson$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Bristol Myers Squibb$739
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$516
- plus $3K from 29 others
What the payments were for
- Speaking & faculty fees$32,91072%
- Travel & lodging$1,7914%
- Food & beverage$11,06324%
- Education$1090%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 108 | $37,269 |
| AbbVie(2 entities) | 82 | $1,644 |
| Johnson & Johnson(2 entities) | 78 | $1,569 |
| Takeda Pharmaceuticals U.S.A., Inc. | 72 | $1,064 |
| Bristol Myers Squibb | 50 | $739 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 27 | $516 |
| E.r. Squibb & Sons, L.L.C. | 4 | $410 |
| Madrigal Pharmaceuticals | 29 | $366 |
| Braintree Laboratories, Inc. | 16 | $324 |
| Vivus LLC | 13 | $263 |
| Redhill Biopharma Inc. | 8 | $255 |
| Romark Laboratories, LC | 6 | $153 |
| Lilly USA, LLC | 6 | $153 |
| Janssen Scientific Affairs, LLC | 1 | $125 |
| Pfizer | 5 | $115 |
| Medtronic | 1 | $91 |
| Intercept Pharmaceuticals, Inc. | 4 | $80 |
| Ardelyx, Inc. | 3 | $78 |
| Alnylam Pharmaceuticals Inc. | 3 | $77 |
| Ironwood Pharmaceuticals, Inc | 4 | $72 |
| Phathom Pharmaceuticals, Inc. | 3 | $72 |
| UCB, Inc. | 3 | $59 |
| Philips North America LLC | 3 | $52 |
| Merck | 3 | $45 |
| Shionogi Inc | 2 | $43 |
| Nestle Healthcare Nutrition Inc. | 2 | $40 |
| Echosens North America, Inc. | 1 | $35 |
| Aimmune Therapeutics, Inc. | 1 | $27 |
| Biocon Biologics Inc | 1 | $25 |
| Sanofi | 1 | $24 |
| Novo Nordisk | 1 | $22 |
| Ferring Pharmaceuticals Inc. | 1 | $22 |
| Celltrion USA Inc. | 1 | $17 |
| QOL Medical, LLC | 1 | $16 |
| Pacira Pharmaceuticals Incorporated | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$45,873 in reported general payments places this provider in the 85th percentile of 1,350 gastroenterology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 75 | $62,475 |
| XifaxanRifaximin | 16 | $52,249 |
| VemlidyTenofovir Alafenamide | 26 | $37,250 |
| Lubiprostone | 46 | $8,140 |
| Dexlansoprazole DrDexlansoprazole | 24 | $6,692 |
| Omeprazole | 383 | $5,147 |
| Mesalamine ErMesalamine | 12 | $4,512 |
| Mesalamine | 12 | $3,887 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 240 | $3,661 |
| Famotidine | 221 | $2,560 |
| Nadolol | 42 | $2,360 |
| Bethanechol Chloride | 48 | $2,149 |
| Rabeprazole Sodium | 57 | $2,141 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 169 | $1,856 |
| Tenofovir Disoproxil Fumarate | 12 | $1,400 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $1,644 | $62,47575 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $516 | $52,24916 claims |
| GileadVemlidy | $37,269 | $37,25026 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,350 gastroenterology providers in Texas.
Other gastroenterology in Houston
- Mazen NoureddinHouston$6.1M
- James MaherHouston$5.3M
- Uma MohanHouston$5M
- John VierlingHouston$2.8M
- Bincy AbrahamHouston$2.5M
- Jason HouHouston$2.3M
- Jignesh ShahHouston$1.7M
- Mouhamad Al-SabbaghHouston$1.6M
- Mohamed OthmanHouston$1.6M
- Harry OjeasHouston$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.